A well-known international pharmaceutical company in Britain recently announced that the third phase clinical trial of SGLT2 inhibitor in the treatment of chronic kidney disease ended ahead of schedule because of its remarkable effect.

The new gospel of treating chronic kidney disease! Patients with chronic kidney disease should control their condition, otherwise the deterioration of the condition may progress to renal dialysis and even increase the risk of premature death from heart disease. Fortunately, AstraZeneca, an international pharmaceutical company, recently announced that the third phase clinical trial of DAPA-CKD and SGLT2 inhibitors in the treatment of chronic kidney disease ended early because of its remarkable effect. Mene Pangalos, executive vice president of AstraZeneca biopharmaceutical R&D Company, said that patients treated with SGLT2 inhibitors have received good benefits and hope to change the management of chronic kidney diseases worldwide.

Poor control of chronic kidney disease will increase the risk of renal dialysis and cardiogenic death.

The American Kidney Disease Foundation pointed out that chronic kidney disease is the persistent damage of the kidney for some reason, and the damage is getting bigger and bigger with the passage of time. If chronic kidney disease is not well controlled, it will develop into renal failure, requiring renal dialysis or kidney transplantation. And poor renal function will increase the risk of heart disease and lead to death.

Effectively delay the early termination test of SGLT2 inhibitor for chronic kidney disease.

According to Medscape, DAPA-CKD is a multi-country, multi-center, randomized controlled, double-blind trial with a total of 4,245 patients, which aims to evaluate the efficacy of SGLT2 inhibitor compared with placebo in patients with chronic kidney disease with proteinuria and type 2 diabetes in stage 2-4. The main composite end points of the trial were the deterioration of renal function, end-stage renal disease, renal or cardiogenic death and other factors.

After evaluation by the Independent Data Monitoring Committee, it was shown that the efficacy of SGLT2 inhibitor was better than expected, so it was decided to end the trial ahead of schedule.

SGLT2 inhibitors help to reduce the risk of cardiogenic death.

SGL T2 inhibitor is a sodium glucose co transporter 2 inhibitor (SGLT2 inhibitor), which was originally used to treat poorly controlled adult type 2 diabetes. As a monotherapy, SGL T2 inhibitors can also be used as a part of combined therapy to help diet and exercise, improve blood sugar control, and help to reduce weight and blood pressure. Studies have shown that SGLT2 inhibitors can help reduce the risk of hospitalization for adults with type 2 diabetes due to heart failure and cardiogenic death.

From August, 2065438 to August, 2009, the US Food and Drug Administration (FDA) granted SGLT2 inhibitors the qualification of rapid examination, which was used to delay renal failure and prevent the psychogenic or nephrogenic death of patients with chronic kidney diseases. At present, the application for new indications of SGLT2 inhibitors in the treatment of heart failure is being given priority by FDA, European Drug Administration (EMA) and other regional regulators.

SGLT2 inhibitors are also beneficial to patients with chronic kidney disease and non-type 2 diabetes.

Mene Pangalos, executive vice president of AstraZeneca Biopharmaceutical R&D Company, said: "Patients with chronic kidney disease have limited treatment options, especially those without type 2 diabetes. We are glad that the Committee has come to this conclusion, and the patients receiving treatment have benefited a lot. SGLT2 inhibitors may change the treatment of patients with chronic kidney disease all over the world. 」

The trial executive Committee and its co-chairs, Professor David Wheeler of University College London and Professor Hiddo L. Heerspink of university of groningen Medical Center, said, "It is our honor to participate in this trial. We are pleased with the Committee's recommendations and look forward to sharing the results with the medical community and patients with chronic kidney disease. 」